Caris Life Sciences reported finalized Achieve 1 study results for its multi-cancer early detection test, Caris Detect, sending shares higher. The study enrolled 3,014 patients who were evaluable based on high-risk screening, symptomatic presentation, or findings from imaging. Caris reported sensitivity across stages, including 60.3% for stage I/II cancers and 98.6% for stage IV, alongside high asymptomatic specificity of 99.2%. Cancer-by-cancer sensitivity ranged from 53.7% in breast cancer to 81.3% in head and neck cancer. In the blinded validation set, a subset of patients lacked staging information or failed sample quality metrics and was excluded from the reported results. Caris also said it plans to add additional modalities such as whole-transcriptome sequencing to further strengthen performance. The company stated it expects to launch Caris Detect in Q2 2026, and stakeholders will now watch for how these finalized metrics translate into intended clinical workflow and prospective validation.